236 related articles for article (PubMed ID: 25682990)
1. Oxidation-specific epitopes are major targets of innate immunity in atherothrombosis.
Bartolini Gritti B; Binder CJ
Hamostaseologie; 2016 May; 36(2):89-96. PubMed ID: 25682990
[TBL] [Abstract][Full Text] [Related]
2. Atherogenesis - tried and tested pieces in the puzzle.
Scharf RE
Hamostaseologie; 2016 May; 36(2):73-4. PubMed ID: 27163332
[No Abstract] [Full Text] [Related]
3. The innate immune response to products of phospholipid peroxidation.
Weismann D; Binder CJ
Biochim Biophys Acta; 2012 Oct; 1818(10):2465-75. PubMed ID: 22305963
[TBL] [Abstract][Full Text] [Related]
4. Oxidative stress, NADPH oxidases, and arteries.
Sun QA; Runge MS; Madamanchi NR
Hamostaseologie; 2016 May; 36(2):77-88. PubMed ID: 25649240
[TBL] [Abstract][Full Text] [Related]
5. Potential cell-specific functions of CXCR4 in atherosclerosis.
Weber C; Döring Y; Noels H
Hamostaseologie; 2016 May; 36(2):97-102. PubMed ID: 25586789
[TBL] [Abstract][Full Text] [Related]
6. Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis.
Leibundgut G; Witztum JL; Tsimikas S
Curr Opin Pharmacol; 2013 Apr; 13(2):168-79. PubMed ID: 23541680
[TBL] [Abstract][Full Text] [Related]
7. Oxidation-specific epitopes are important targets of innate immunity.
Chou MY; Hartvigsen K; Hansen LF; Fogelstrand L; Shaw PX; Boullier A; Binder CJ; Witztum JL
J Intern Med; 2008 May; 263(5):479-88. PubMed ID: 18410591
[TBL] [Abstract][Full Text] [Related]
8. Oxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics.
Miller YI; Tsimikas S
Curr Opin Lipidol; 2013 Oct; 24(5):426-37. PubMed ID: 23995232
[TBL] [Abstract][Full Text] [Related]
9. The OSE complotype and its clinical potential.
Alic L; Binder CJ; Papac-Milicevic N
Front Immunol; 2022; 13():1010893. PubMed ID: 36248824
[TBL] [Abstract][Full Text] [Related]
10. Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease.
Gounopoulos P; Merki E; Hansen LF; Choi SH; Tsimikas S
Minerva Cardioangiol; 2007 Dec; 55(6):821-37. PubMed ID: 18091649
[TBL] [Abstract][Full Text] [Related]
11. Natural IgM antibodies against oxidation-specific epitopes.
Binder CJ
J Clin Immunol; 2010 May; 30 Suppl 1():S56-60. PubMed ID: 20387104
[TBL] [Abstract][Full Text] [Related]
12. Naturally occurring IgM antibodies to oxidation-specific epitopes.
Binder CJ
Adv Exp Med Biol; 2012; 750():2-13. PubMed ID: 22903662
[TBL] [Abstract][Full Text] [Related]
13. B cells and atherosclerosis.
Srikakulapu P; McNamara CA
Am J Physiol Heart Circ Physiol; 2017 May; 312(5):H1060-H1067. PubMed ID: 28314764
[TBL] [Abstract][Full Text] [Related]
14. Innate sensing of oxidation-specific epitopes in health and disease.
Binder CJ; Papac-Milicevic N; Witztum JL
Nat Rev Immunol; 2016 Aug; 16(8):485-97. PubMed ID: 27346802
[TBL] [Abstract][Full Text] [Related]
15. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans.
Chou MY; Fogelstrand L; Hartvigsen K; Hansen LF; Woelkers D; Shaw PX; Choi J; Perkmann T; Bäckhed F; Miller YI; Hörkkö S; Corr M; Witztum JL; Binder CJ
J Clin Invest; 2009 May; 119(5):1335-49. PubMed ID: 19363291
[TBL] [Abstract][Full Text] [Related]
16. Imaging of oxidation-specific epitopes with targeted nanoparticles to detect high-risk atherosclerotic lesions: progress and future directions.
Briley-Saebo K; Yeang C; Witztum JL; Tsimikas S
J Cardiovasc Transl Res; 2014 Nov; 7(8):719-36. PubMed ID: 25297940
[TBL] [Abstract][Full Text] [Related]
17. Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies.
Tsiantoulas D; Perkmann T; Afonyushkin T; Mangold A; Prohaska TA; Papac-Milicevic N; Millischer V; Bartel C; Hörkkö S; Boulanger CM; Tsimikas S; Fischer MB; Witztum JL; Lang IM; Binder CJ
J Lipid Res; 2015 Feb; 56(2):440-8. PubMed ID: 25525116
[TBL] [Abstract][Full Text] [Related]
18. The role of innate immunity in atherogenesis.
Hartvigsen K; Chou MY; Hansen LF; Shaw PX; Tsimikas S; Binder CJ; Witztum JL
J Lipid Res; 2009 Apr; 50 Suppl(Suppl):S388-93. PubMed ID: 19106070
[TBL] [Abstract][Full Text] [Related]
19. Low levels of IgM antibodies recognizing oxidation-specific epitopes are associated with human non-alcoholic fatty liver disease.
Hendrikx T; Watzenböck ML; Walenbergh SM; Amir S; Gruber S; Kozma MO; Grabsch HI; Koek GH; Pierik MJ; Staufer K; Trauner M; Kalhan SC; Jonkers D; Hofker MH; Binder CJ; Shiri-Sverdlov R
BMC Med; 2016 Jul; 14(1):107. PubMed ID: 27443391
[TBL] [Abstract][Full Text] [Related]
20. Immunization with malondialdehyde-modified low-density lipoprotein (LDL) reduces atherosclerosis in LDL receptor-deficient mice challenged with Porphyromonas gingivalis.
Turunen SP; Kummu O; Wang C; Harila K; Mattila R; Sahlman M; Pussinen PJ; Hörkkö S
Innate Immun; 2015 May; 21(4):370-85. PubMed ID: 25134521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
